Literature DB >> 12297900

Increased serum granulocyte colony-stimulating factor correlates with coronary artery dilatation in Kawasaki disease.

Kazunori Samada1, Hiroshi Igarashi, Hirohiko Shiraishi, Kiyohiko Hatake, Mariko Y Momoi.   

Abstract

UNLABELLED: In acute-phase Kawasaki disease, neutrophils cause injury to the coronary arterial endothelium through the production of elastase. Previous research has demonstrated the modulation of neutrophil function and kinetics, such as development and maturation, by granulocyte colony-stimulating factor (G-CSF). To examine the correlation between G-CSF and cardiac complications in Kawasaki disease, functional activity of serum G-CSF and cytokines was measured by enzyme-linked immunosorbent assay in 30 patients with acute-phase Kawasaki disease aged 2 months to 5 years. The mean serum G-CSF was higher in the 1st week of Kawasaki disease than during weeks 2 to 4, and G-CSF was significantly higher in patients with coronary artery dilatation (CAL) than in those without. There was no significant difference in the activity of other cytokines studied or white blood cell counts between the patients with CAL.
CONCLUSION: granulocyte colony-stimulating factor is correlated with coronary artery dilatation in acute-phase Kawasaki disease and increased neutrophil function may contribute to the pathogenesis of coronary arterial endothelial injury in these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297900     DOI: 10.1007/s00431-002-1018-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  7 in total

1.  [Fever, bilateral conjunctivitis, cervical lymphadenopathy, lacquered lips and rash].

Authors:  S Cantemir; S Flüshöh; G Koch; A Laubert
Journal:  HNO       Date:  2004-04       Impact factor: 1.284

2.  Effects of G-CSF on serum cholesterol and development of atherosclerotic plaque in apolipoprotein E-deficient mice.

Authors:  Satyesh K Sinha; Vivek Mishra; Santosh Nagwani; Tripathi B Rajavashisth
Journal:  Int J Clin Exp Med       Date:  2014-08-15

3.  Increased CD11b expression on polymorphonuclear leucocytes and cytokine profiles in patients with Kawasaki disease.

Authors:  T Kobayashi; H Kimura; Y Okada; Y Inoue; T Kobayashi; M Shinohara; A Morikawa
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

4.  Markedly elevated CD64 expression on neutrophils and monocytes as a biomarker for diagnosis and therapy assessment in Kawasaki disease.

Authors:  Sho Hokibara; Norimoto Kobayashi; Keiko Kobayashi; Tomonari Shigemura; Haruo Nagumo; Masahiro Takizawa; Takashi Yamazaki; Kazunaga Agematsu
Journal:  Inflamm Res       Date:  2016-03-28       Impact factor: 4.575

5.  Parameters to guide retreatment after initial intravenous immunoglobulin therapy in kawasaki disease.

Authors:  Hyun Kwon Kim; Jungeun Oh; Young Mi Hong; Sejung Sohn
Journal:  Korean Circ J       Date:  2011-07-30       Impact factor: 3.243

6.  Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-γ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome.

Authors:  Francesca Caldarale; Mauro Giacomelli; Emirena Garrafa; Nicola Tamassia; Alessia Morreale; Piercarlo Poli; Silviana Timpano; Giulia Baresi; Fiammetta Zunica; Marco Cattalini; Daniele Moratto; Marco Chiarini; Elvira Stefania Cannizzo; Giulia Marchetti; Marco Antonio Cassatella; Andrea Taddio; Alberto Tommasini; Raffaele Badolato
Journal:  Front Immunol       Date:  2021-03-26       Impact factor: 7.561

7.  MicroRNA-145-5p and microRNA-320a encapsulated in endothelial microparticles contribute to the progression of vasculitis in acute Kawasaki Disease.

Authors:  Hideyuki Nakaoka; Keiichi Hirono; Seiji Yamamoto; Ichiro Takasaki; Kei Takahashi; Koshi Kinoshita; Asami Takasaki; Naonori Nishida; Mako Okabe; Wang Ce; Nariaki Miyao; Kazuyoshi Saito; Keijiro Ibuki; Sayaka Ozawa; Yuichi Adachi; Fukiko Ichida
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.